Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bluebird bio

- PMLiVE

New hires at bluebird bio, BioNTech and Provention Bio

The latest movers in pharma

- PMLiVE

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

Will offer treatment via an outcomes-based payment model

Life with multiple myeloma – why I’m a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling...

Blue Latitude Health

- PMLiVE

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

- PMLiVE

FDA backs GBT’s sickle cell drug Oxbryta

Second new treatment for blood disorder to be approved this year

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

- PMLiVE

bluebird bio reveals further encouraging data for CALD gene therapy

Study shows continued benefit in treatment of rare disease

- PMLiVE

FDA starts speedy review of Novartis’ sickle cell antibody

Among several $1bn+ late-stage drugs in company's pipeline

- PMLiVE

Bluebird puts €1.57m price on gene therapy Zynteglo

US biotech pioneering outcomes-based payment in Europe

- PMLiVE

A first for Bluebird and Europe as gene therapy Zynteglo approved

Will product be priced over $1m?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links